Advanced Search

 

Study ID Status Title Patient Level Data
49653/048 Completed A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients with Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
49653/049 Completed A Study to Determine the Balance/Excretion, Pharmacokinetics and Biotransformation of BRL 49653 Given as a Single Oral (8 mg pfb) and Single Intravenous (2 mg pfb) Doses of [14C]-BRL 49653C to Healthy Male Adult Volunteers and Determine the Pharmacokinetics of a Single Oral Dose (2 x 4 mg Tablet ...
49653/050 Completed A Clinical Evaluation of BRL49653C in Type-2 Diabetes Mellitus; An Early Phase II Open-label Study (Monotherapy)
49653/051 Completed A Clinical Evaluation of BRL49653C in Non-insulin-dependent Diabetes Mellitus.
49653/054 Completed Clinical Evaluation of BRL49653C in Type-2 Diabetes Mellitus (Monotherapy) - Double-blind Dose-finding Study.
49653/055 Completed Clinical Evaluation of BRL49653C in Type-2 Diabetes Mellitus (Combination Therapy with Sulphonylurea) - Double-blind Dose-finding Study.
49653/078 Completed A Placebo-controlled Study to Evaluate the Effect of Rosiglitazone on Plasma Volume and Red Blood Cell Volume in Healthy Volunteers
49653/079 Completed A 26-week Randomized, Double-Blind, Double-Dummy, Multicentered Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on a Maximal Dose (20 mg/day) of Glyburide. Study Listed on ClinicalStudyDataRequest.com
49653/080 Completed A 3 Year Open-label, Multicenter, Active (Glyburide) Comparison Study to Evaluate the Effect of Rosiglitazone on Cardiovascular Function in Patients with Non-insulin Dependent Diabetes Mellitus (NIDDM)
49653/082 Completed A 26-Week Randomized, Double-Blind, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of BRL 49653C when Administered Twice Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on Insulin Monotherapy Study Listed on ClinicalStudyDataRequest.com
49653/083 Completed Investigation of the effects of the thiazolidinedione, rosiglitazone, on regional adiposity, intrahepatic fat and muscle insulin sensitivity in type 2 diabetic patients (TRIM)
49653/084 Completed An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of BRL 49653C when Administered as Monotherapy, Twice Daily, to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
49653/085 Completed A 26 Week Randomised, Double-Blind, Multicentre Study to Investigate the Effects of Rosiglitazone on Insulin Requirements in Insulin-Treated Type 2 Diabetic Patients Study Listed on ClinicalStudyDataRequest.com
49653/087 Completed A Placebo-controlled Single-blind Study on the Safety, Tolerance and Pharmacokinetics of Single and 7-day (b.i.d.) Repeat Oral Administration of BRL49653C 4mg in Healthy Adult Volunteers.
49653/090 Completed An 8-week Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Rosiglitazone (BRL 49653) Therapy when Administered to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) Using a Twice Daily D ...
49653/091 Completed A Multicentre, Open Label Extension Study To Assess the Long Term Safety, Tolerability and Efficacy of Rosiglitazone when Administered as Monotherapy, Once Daily to Patients with Type 2 Diabetes Mellitus
49653/093 Completed A 26-Week Randomized, Double-Blind, Double-Dummy, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone 4mg twice daily when Administered to Subjects with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on a Maintenance Dose (2.5mg/d ...
49653/094 Completed A 26-Week Randomized, Double-Blind, Double-Dummy, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on a Maintenance Dose (2.5 mg/day) ...
49653/095 Completed A 26-week Randomised, Double-Blind, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Type 2 Diabetes who are Inadequately Controlled on Insulin Monotherapy Study Listed on ClinicalStudyDataRequest.com
49653/096 Completed A 26-week Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on… Study Listed on ClinicalStudyDataRequest.com
49653/097 Completed A 3-Year Open-Label, Multicenter, Active (Glyburide) Comparison Study, to Evaluate the Effect of BRL49653C 8mg once daily on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) Study Listed on ClinicalStudyDataRequest.com
49653/098 Completed A Multicentre, Double-Blind, Parallel Group, Placebo-Controlled Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone When Administered Once Daily to Patients with Type 2 Diabetes Mellitus
49653/101 Completed A placebo controlled single-blind study on the safety, tolerance and pharmacokinetics of single and 8-day (u.i.d) repeat oral administration of BRL 49653C 8 mg in healthy adult volunteers
49653/105 Completed An Open-label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of BRL 49653C When Administered as Monotherapy, Once Daily, to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
49653/108 Completed A 16-Week Randomized, Double-Blind, Parallel-Group Study to Evaluate the Safety and Efficacy of Hypolipidemic Therapy with an HMGCoA Reductase Inhibitor (Atorvastatin) in Type 2 Diabetes Mellitus Patients Treated with Rosiglitazone (BRL 49653C) 4mg bd

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.